(Q53280240)

12 May 2018

title

Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. (English)

1 reference

12 May 2018

lymphoproliferative disorders

main subject

1 reference

1 reference

1

Irene M Ghobrial

1 reference

12 May 2018

author name string

Thomas M Habermann

2

1 reference

12 May 2018

Kay M Ristow

3

1 reference

12 May 2018

Stephen M Ansell

4

1 reference

12 May 2018

William Macon

5

1 reference

12 May 2018

Suzan M Geyer

6

1 reference

12 May 2018

Christopher G McGregor

7

1 reference

12 May 2018

publication date

1 February 2005

1 reference

12 May 2018

published in

Leukemia & Lymphoma

1 reference

12 May 2018

volume

46

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

191-196

1 reference

12 May 2018

Anti-B cell and anti-cytokine therapy for the treatment of post-transplant lymphoproliferative disorder: past, present, and future.

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190400012011

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400012011

Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400012011

Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400012011

Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400012011

Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400012011

Non-Hodgkin's lymphoma: present status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400012011

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400012011

Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400012011

Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400012011

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400012011

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400012011

10.1080/10428190400012011

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018